Cavidi closes US$ 11.5 million financing with Impilo
“We launched development of the Ziva platform with a loan from the European Investment Bank, our first institutional capital.We have now largely completed Ziva development and established a distribution agreement with a top 10 global diagnostic company. With this financing, we have secured the growth equity to support Ziva’s launch.
CAVIDI secures €7.8 million in new investment
Cavidi, a Swedish diagnostics company supplying HIV monitoring tests in global markets, announced today it had closed on an underwritten equity injection of €3.30 million from existing and five new investors and by so doing secured debt financing in the amount of €4.50 million.
Cavidi at ASLM2016
ASLM2016 is the third biennial international conference of the African Society for Laboratory Medicine (ASLM). It is being held in Cape Town, South Africa from 3rd December to 8thDecember.
Partners in Health begin VL testing at St Marc Clinic, Haiti
HIV patients at the Partners in Health St Marc Clinic in Haiti will now be receiving regular Viral Load testing. The clinic will be using Cavidi's ExaVir Load Viral Load test to follow-up and manage the treatment of people living with HIV for better treatment outcomes.
Cavidi invited to present at BIO 2016 in San Francisco
The BIO International Convention 2016 returns to its roots by being held in San Francisco, California USA. Cavidi will be presenting at the event on invitation from the European Commission. John Reisky de Dubnic CEO of Cavidi will talk about Cavidi and the European Investment Bank program InnovFin.
Cavidi Selected to Present at Cavendish Global Health Impact Forum
Stockholm 15th February 2016 — Cavidi a specialist HIV monitoring company, announced today it has been selected to present at the Cavendish Global Health Impact Forum taking place February 15th to February 18th at the Breakers in Palm Beach, Florida.
$16 Billion Market for Infectious Disease Testing
January 27, 2016 Genetic Engineering & Biotechnology News sites Cavidi technology as a novel approach to addressing the challenges of microbial resistance that is on the rise. Healthcare is now looking to testing and monitoring to halt the global surge of bacterial infection.
Newly published study from India shows ExaVir Load as suitable and inexpensive for resource-poor settings
A study published in Dec 2015 by Priyadarshini A. Padaki et al. from CMC Vellore, India, evaluated Cavidi’s viral load ExaVir Load for use in resource limited settings and compared it with two PCR assays. Compared with the routine molecular viral load assays, Cavidi version 3.
Cavidi co-sponsor of ICASA 2015
The 18th ICASA is underway in Zimbabwe with a focus on gaining commitment to achieve an AIDS-free Africa. Cavidi is a co-sponsor of the event and we see the use of viral load testing as an integral part of achieving that aim.
EIB supports Cavidi’s development of HIV viral load monitoring device
The European Investment Bank (EIB) has provided a EUR 10 million long-term loan to Swedish biotech company Cavidi AB for developing a next generation automated testing device for HIV viral load.